Brand name: RayStation. Generic name: Treatment Planning System. Software version and build numbers are 2.5.0.144 and 2.5.1.89. Product lifetime is 5 years. RayStation is a software system designed for treatment planning and analysis of radiation therapy. The treatment plans provide treatment unit set-up parameters and estimates of dose distributions expected during the proposed treatment, and may be used to administer treatments after review and approval by the intended user. The system functionality can be configured based on user needs. The intended users of RayStation shall be clinically qualified radiation therapy staff trained in using the system.
Publicado el 12 de septiembre de 2012 · Inicio del retiro: 9 de mayo de 2012
Resumen
FDA registra el retiro Z-2324-2012 de dispositivos médicos de Clase II, publicado el 12 de septiembre de 2012 e iniciado el 9 de mayo de 2012. Empresa responsable: RAYSEARCH LABORATORIES AB; Estado: Finalizado; Cantidad reportada: 19 units; Lote: Software version and build numbers are 2.5.0.144 and 2.5.1.89. Product lifetime is 5 years. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
The firm decided to recall when an issue was found with the dose calculation in RayStation 2.5, Raystation 2.5.1. The problem has not caused any patient mistreatment or other incidents. However, the user must be aware of this information to avoid incorrect dose calculations during treatment planning. The dose calculation is not correctly normalized in the unusual case of preventing the optimizatio
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- RAYSEARCH LABORATORIES AB
- Distribuidor
- Worldwide distribution: USA (nationwide) including states of: FL, MA, NJ, and NY; and countries of: Canada Germany, Netherlands and Switzerland.
- Lote
- Software version and build numbers are 2.5.0.144 and 2.5.1.89. Product lifetime is 5 years.
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- Sweden
Retiros relacionados
- FDARayCare 2024A SP4. Oncology Information Systems.8 de julio de 2026
- FDARayCare 2024A SP1. Oncology Information Systems.8 de julio de 2026
- FDABrand Name: RayStation Product Name: RayStation/RayPlan Model/Catalog Number: 14.0.0, 15.0.0, 15.1.3 Software28 de enero de 2026
- FDABrand Name: RayStation Product Name: RayStation/RayPlan Model/Catalog Number: 17.0.0, 17.0.1 Software Version:28 de enero de 2026
- FDAVersaTREK Windows Software, Version 5.4.3 is a component of the VersaTrek System. The Software CD will be12 de septiembre de 2012
- FDA100 ft roll of tubing inside a cardboard box. Medical devices are sealed into the tubes prior to ethylene12 de septiembre de 2012
Preguntas sobre este retiro
¿Brand name: RayStation. Generic name: Treatment Planning System. Software version and build numbers are 2.5.0.144 and 2.5.1.89. Product lifetime is 5 years. RayStation is a software system designed for treatment planning and analysis of radiation therapy. The treatment plans provide treatment unit set-up parameters and estimates of dose distributions expected during the proposed treatment, and may be used to administer treatments after review and approval by the intended user. The system functionality can be configured based on user needs. The intended users of RayStation shall be clinically qualified radiation therapy staff trained in using the system. fue retirado del mercado?
Sí. FDA publicó el retiro Z-2324-2012 el 12 de septiembre de 2012. Peligro reportado: The firm decided to recall when an issue was found with the dose calculation in RayStation 2.5, Raystation 2.5.1. The problem has not caused any patient mistreatment or other incidents. However, the user must be aware of this information to avoid incorrect dose calculations during treatment planning. The dose calculation is not correctly normalized in the unusual case of preventing the optimizatio
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter